|
Individual response
|
|
61
|
4552
|
January 22, 2022
|
|
Bernoulli trials vs completely randomized trials
|
|
0
|
200
|
January 5, 2022
|
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
284
|
December 28, 2021
|
|
Cost-effectiveness based interim analysis
|
|
2
|
254
|
December 15, 2021
|
|
Language for communicating frequentist results about treatment effects
|
|
193
|
54630
|
November 1, 2021
|
|
Interpretation of the REGEN-COV trial
|
|
22
|
1206
|
November 1, 2021
|
|
Evidence Based Decision Making and Meta-Analysis -- An Information Theoretic Critique
|
|
0
|
566
|
October 27, 2021
|
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
10307
|
October 8, 2021
|
|
Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
898
|
September 2, 2021
|
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
1055
|
August 8, 2021
|
|
Heterogeneity in RCTs with continuous outcome
|
|
19
|
2343
|
July 2, 2021
|
|
Default Using R package to implement Bayesian phase I/II dose-finding design for three outcomes
|
|
10
|
1284
|
June 10, 2021
|
|
Summary Statistics vs Raw Data
|
|
7
|
2808
|
February 28, 2021
|
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
8
|
1565
|
February 24, 2021
|
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
1396
|
December 30, 2020
|
|
What is a fake measurement tool and how are they used in RCT
|
|
44
|
5062
|
December 20, 2020
|
|
Quality of remdesivir trials
|
|
41
|
6050
|
November 18, 2020
|
|
RCT trials for COVID study vaccines
|
|
0
|
1373
|
October 24, 2020
|
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
1584
|
October 13, 2020
|
|
"Open label, double-masked trial"
|
|
0
|
1537
|
October 13, 2020
|
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
1477
|
September 30, 2020
|
|
Time since randomization and causality
|
|
2
|
1318
|
September 27, 2020
|
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
3006
|
September 22, 2020
|
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
3341
|
August 11, 2020
|
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
1553
|
August 11, 2020
|
|
MERINO trial - adjusting for infection source
|
|
3
|
1823
|
August 3, 2020
|
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
2164
|
July 19, 2020
|
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
2025
|
June 15, 2020
|
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
1914
|
May 15, 2020
|
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
2242
|
March 11, 2020
|
